Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
UPI's Cash to Debt is ranked higher than
100% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. UPI: No Debt )
UPI' s 10-Year Cash to Debt Range
Min: 1.25   Max: No Debt
Current: No Debt

Equity to Asset 0.73
UPI's Equity to Asset is ranked higher than
79% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. UPI: 0.73 )
UPI' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.91
Current: 0.73

0.39
0.91
Interest Coverage No Debt
UPI's Interest Coverage is ranked higher than
74% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. UPI: No Debt )
UPI' s 10-Year Interest Coverage Range
Min: 3.21   Max: 9999.99
Current: No Debt

3.21
9999.99
F-Score: 4
Z-Score: 4.45
M-Score: -3.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -19.61
UPI's Operating margin (%) is ranked higher than
54% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.93 vs. UPI: -19.61 )
UPI' s 10-Year Operating margin (%) Range
Min: -87.55   Max: 15.27
Current: -19.61

-87.55
15.27
Net-margin (%) -19.87
UPI's Net-margin (%) is ranked higher than
54% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. UPI: -19.87 )
UPI' s 10-Year Net-margin (%) Range
Min: -73.95   Max: 9.41
Current: -19.87

-73.95
9.41
ROE (%) -40.16
UPI's ROE (%) is ranked higher than
52% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.73 vs. UPI: -40.16 )
UPI' s 10-Year ROE (%) Range
Min: -146.57   Max: 24.87
Current: -40.16

-146.57
24.87
ROA (%) -30.92
UPI's ROA (%) is ranked higher than
51% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. UPI: -30.92 )
UPI' s 10-Year ROA (%) Range
Min: -83.79   Max: 15.34
Current: -30.92

-83.79
15.34
ROC (Joel Greenblatt) (%) -321.04
UPI's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. UPI: -321.04 )
UPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -352.19   Max: 77.16
Current: -321.04

-352.19
77.16
Revenue Growth (%) 16.70
UPI's Revenue Growth (%) is ranked higher than
91% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. UPI: 16.70 )
UPI' s 10-Year Revenue Growth (%) Range
Min: -23.7   Max: 16.7
Current: 16.7

-23.7
16.7
EBITDA Growth (%) 6.60
UPI's EBITDA Growth (%) is ranked higher than
81% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. UPI: 6.60 )
UPI' s 10-Year EBITDA Growth (%) Range
Min: -38.3   Max: 214.1
Current: 6.6

-38.3
214.1
» UPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

UPI Guru Trades in Q3 2013

Jim Simons 73,000 sh (+54.33%)
» More
Q4 2013

UPI Guru Trades in Q4 2013

Jim Simons 78,100 sh (+6.99%)
» More
Q1 2014

UPI Guru Trades in Q1 2014

Jim Simons 91,300 sh (+16.9%)
» More
Q2 2014

UPI Guru Trades in Q2 2014

Jim Simons 123,178 sh (+34.92%)
» More
» Details

Insider Trades

Latest Guru Trades with UPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.70
UPI's P/B is ranked higher than
63% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. UPI: 4.70 )
UPI' s 10-Year P/B Range
Min: 0.44   Max: 11.07
Current: 4.7

0.44
11.07
P/S 2.10
UPI's P/S is ranked higher than
75% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. UPI: 2.10 )
UPI' s 10-Year P/S Range
Min: 0.38   Max: 11.49
Current: 2.1

0.38
11.49
EV-to-EBIT -7.88
UPI's EV-to-EBIT is ranked higher than
52% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 34.56 vs. UPI: -7.88 )
UPI' s 10-Year EV-to-EBIT Range
Min: -33.4   Max: 0.9
Current: -7.88

-33.4
0.9
Current Ratio 4.11
UPI's Current Ratio is ranked higher than
82% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. UPI: 4.11 )
UPI' s 10-Year Current Ratio Range
Min: 1.72   Max: 13.51
Current: 4.11

1.72
13.51
Quick Ratio 3.94
UPI's Quick Ratio is ranked higher than
86% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. UPI: 3.94 )
UPI' s 10-Year Quick Ratio Range
Min: 1.34   Max: 13.24
Current: 3.94

1.34
13.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.17
UPI's Price/Net Cash is ranked higher than
94% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. UPI: 8.17 )
UPI' s 10-Year Price/Net Cash Range
Min: 1.81   Max: 107.2
Current: 8.17

1.81
107.2
Price/Net Current Asset Value 6.08
UPI's Price/Net Current Asset Value is ranked higher than
91% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. UPI: 6.08 )
UPI' s 10-Year Price/Net Current Asset Value Range
Min: 1.32   Max: 26
Current: 6.08

1.32
26
Price/Tangible Book 4.65
UPI's Price/Tangible Book is ranked higher than
72% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 6.00 vs. UPI: 4.65 )
UPI' s 10-Year Price/Tangible Book Range
Min: 0.76   Max: 12.77
Current: 4.65

0.76
12.77
Price/Median PS Value 0.66
UPI's Price/Median PS Value is ranked higher than
91% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.13 vs. UPI: 0.66 )
UPI' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 4.75
Current: 0.66

0.14
4.75
Earnings Yield (Greenblatt) -12.30
UPI's Earnings Yield (Greenblatt) is ranked lower than
51% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. UPI: -12.30 )
UPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 113.7   Max: 786.1
Current: -12.3

113.7
786.1
Forward Rate of Return (Yacktman) -1.77
UPI's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.44 vs. UPI: -1.77 )
UPI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -120.1   Max: 10.1
Current: -1.77

-120.1
10.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Uroplasty, Inc. was incorporated in January 1992 as a Minnesota Corporation and a wholly owned subsidiary of its original parent. In February 1995, it became a stand-alone, privately held company to a Plan of Reorganization confirmed by the U.S. Bankruptcy Court. It is a medical device Company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. The Company focuses on two products: Urgent PC system, which is the only FDA-approved minimally-invasive, office-based neurostimulation therapy for the treatment of urinary urgency, urinary frequency, and urge incontinence - symptoms often associated with overactive bladder (OAB); and Macroplastique, a urethral bulking agent for the treatment of adult female stress urinary incontinence mainly due to intrinsic sphincter deficiency (ISD). The physicians prefer its products because they offer an effective therapy for the patient, could be administered in office-based settings and, to the extent reimbursement are in place, provide the physicians a new profitable recurring revenue stream. The patients prefer its products because they are minimally invasive treatment alternatives and neither have the side effects associated with pharmaceutical treatment options nor the morbidity associated with surgery. The Company has a U.S. Food and Drug Administration (FDA)-qualified manufacturing facility in Minnetonka, Minnesota. It uses only medical grade solid silicone material in its tissue bulking products and do not use semi-liquid silicone gel, as was used in breast implants. Competitors offer management and curative treatments, including neurostimulation devices, tissue bulking agents and urethral sling products. The Company has registered Uroplasty, Macroplastique, VOX, PTQ and Bioplastique as trademarks with the U.S. Patent and Trademark Office and throughout the European Union. The testing, manufacturing, promotion, marketing and distribution of its products in the United States, Europe and other parts of the world are subject to regulation by numerous governmental authorities, including the FDA, the European Union and other analogous agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK